Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide in T2DM with Metformin or Sulfonylureas
NCT00324363Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2006
- Primary completion
- Apr 2007
- Modality
- Peptides
- Countries
- 4
01
Overview
A Phase 3 trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Jan 2006; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00324363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00324363.